155 related articles for article (PubMed ID: 36432729)
1. Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.
Eljack S; Allard-Vannier E; Misericordia Y; Hervé-Aubert K; Aubrey N; Chourpa I; Faggad A; David S
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432729
[TBL] [Abstract][Full Text] [Related]
2. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
3. Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment.
Eljack S; David S; Chourpa I; Faggad A; Allard-Vannier E
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558904
[TBL] [Abstract][Full Text] [Related]
4. Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
Suo A; Qian J; Xu M; Xu W; Zhang Y; Yao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():659-672. PubMed ID: 28482576
[TBL] [Abstract][Full Text] [Related]
5. Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics.
Bruniaux J; Djemaa SB; Hervé-Aubert K; Marchais H; Chourpa I; David S
Int J Pharm; 2017 Nov; 532(2):660-668. PubMed ID: 28506802
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.
Abedin MR; Powers K; Aiardo R; Barua D; Barua S
Sci Rep; 2021 Apr; 11(1):7347. PubMed ID: 33795712
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
9. Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.
Ghosh SK; Yigit MV; Uchida M; Ross AW; Barteneva N; Moore A; Medarova Z
Int J Cancer; 2014 Apr; 134(7):1758-66. PubMed ID: 24114765
[TBL] [Abstract][Full Text] [Related]
10. Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells.
Papanikolaou V; Iliopoulos D; Dimou I; Dubos S; Kappas C; Kitsiou-Tzeli S; Tsezou A
J Cell Mol Med; 2011 Jul; 15(7):1542-50. PubMed ID: 20716114
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
12. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin.
Nguyen PL; Elkamhawy A; Choi YH; Lee CH; Lee K; Cho J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077298
[TBL] [Abstract][Full Text] [Related]
14. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
[TBL] [Abstract][Full Text] [Related]
15. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
[TBL] [Abstract][Full Text] [Related]
16. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
Naruphontjirakul P; Viravaidya-Pasuwat K
Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
[No Abstract] [Full Text] [Related]
17. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
Yousefpour P; Atyabi F; Vasheghani-Farahani E; Movahedi AA; Dinarvand R
Int J Nanomedicine; 2011; 6():1977-90. PubMed ID: 21976974
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of doxorubicin and P-glycoprotein siRNA by multifunctional triblock copolymers for enhanced anticancer efficacy in breast cancer cells.
Xu M; Qian J; Suo A; Cui N; Yao Y; Xu W; Liu T; Wang H
J Mater Chem B; 2015 Mar; 3(10):2215-2228. PubMed ID: 32262389
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 functionalized graphene oxide as survivin-siRNA delivery carrier inhibits breast carcinoma growth in vitro and in vivo.
Wang X; Sun Q; Cui C; Li J; Wang Y
Drug Des Devel Ther; 2018; 12():2841-2855. PubMed ID: 30233146
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
